A Phase 2, Randomized, Double-Blind, Parallel, Placebo-Controlled, Proof-of-Concept Study to Assess the Efficacy, Safety, and Tolerability of ASP3291 in Patients With Active Ulcerative Colitis.
Phase of Trial: Phase II
Latest Information Update: 06 Jan 2015
At a glance
- Drugs ASP 3291 (Primary)
- Indications Ulcerative colitis
- Focus Therapeutic Use
- Sponsors Telsar Pharma
- 23 Jun 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 01 Apr 2014 Planned End Date changed from 1 Apr 2014 to 1 May 2014, as per ClinicalTrials.gov record.
- 21 Jan 2014 Status changed from recruiting to active, no longer recruiting according to ClinicalTrials.gov record.